Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Satellos Bioscience ( (TSE:MSCL) ).
Satellos Bioscience announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, where CEO Frank Gleeson will present and engage in one-on-one meetings. This event marks an important opportunity for Satellos to showcase its innovative drug development approach in the muscle disease treatment space and could potentially enhance its industry positioning and stakeholder engagement.
More about Satellos Bioscience
Satellos Bioscience Inc. is a clinical-stage biotech company focused on developing small molecule therapeutics to treat degenerative muscle diseases. Their lead drug candidate, SAT-3247, is designed to restore muscle regeneration in patients with Duchenne muscular dystrophy, using their proprietary MyoReGenX™ platform to identify other muscle regeneration deficits for potential treatment.
YTD Price Performance: -9.98%
Average Trading Volume: 76,614
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $86.31M
Find detailed analytics on MSCL stock on TipRanks’ Stock Analysis page.
